Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-02-07
2006-02-07
Guzo, David (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500
Reexamination Certificate
active
06995146
ABSTRACT:
Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.
REFERENCES:
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 5004810 (1991-04-01), Draper
patent: 5034506 (1991-07-01), Summerton et al.
patent: 5166195 (1992-11-01), Ecker
patent: 5194428 (1993-03-01), Agrawal et al.
patent: 5264423 (1993-11-01), Cohen et al.
patent: 5276017 (1994-01-01), Feinberg et al.
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5627158 (1997-05-01), Cho-Chung
patent: 5714596 (1998-02-01), Houghton et al.
patent: 5922857 (1999-07-01), Han et al.
patent: 6174868 (2001-01-01), Anderson et al.
patent: 2104649 (1993-08-01), None
patent: 318216 (1988-11-01), None
patent: 419182 (1990-09-01), None
patent: WO 94/08002 (1994-04-01), None
patent: WO 94/24864 (1994-11-01), None
Smith et al., PNAS, 1986, vol. 83, pp. 2787-2791.
Storey et al., Nucleic Acids Res., Aug. 1991, vol. 19, No. 15, pp. 4109-4114.
Choo et al., “Isolation of a cDNA Clone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis Genome”,Science1989 244:359-362.
Choo et al., “Genetic organization and diversity of the hepatitis C virus”,Proc. Natl. Acad. Sci.1991 88:2451-2455.
BioWorld Today, Apr. 29, 1994 p. 3.
Egholm et al., “Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone”,J. Am. Chem. Soc.1992 114:1895.
Egholm et al., “Recognition of Guanine and Adenine in DNA by Cytosine and Thymine Containing Peptide Nucleic Acids (PNA)”,J. Am. Chem. Soc.1992 114:9677.
Han et al., “Characterization of the terminal regions of hepatitis C viral RNA: Identification of conserved sequences in the 5′ untranslated region and poly (A) tails at the 3′ end,”Proc. Natl. Acad. Sci. 1991 88:1711-1715.
Inchauspe et al., “Genomic structure of the human prototype strain H of hepatitis C virus: Comparison with American and Japanese isolates,”Proc. Natl. Acad. Sci.1991 88:10292-10296.
Inoue et al., “Synthesis and hybridization studies on two complementary nona(2′-O-methyl)ribonucleotides,”Nucleic Acids Research1991 15:6131-6148.
Nielsen et al., “Sequence-selective recognition of DNA by Strand displacement with a thymine-substituted polyamide,”Science1991 254:1497-1500.
Sproat et al., “New synthetic routes to protected purine 2′-O-methylriboside-3′-O-phosphoramidites using a novel alkylation procedure,”Nucleic Acids Research18:41-49.
Takamizawa et al., “Structure and organization of the hepatitis C virus genome isolated from human carriers,”J. Virol. 1991 65:1105-1113.
Tsukiyama-Kohara et al., “Internal ribosome entry site within hepatitis C virus RNA,”J. Virol. 1992 66:1476-1483.
Vasseur et al., “Oligonucleosides: Synthesis of a Novel Methylhydroxylamine-Linked Nucleoside Dimer and Its Incorporation into Antisense Sequences”,J. Am. Chem. Soc. 1992 114:4006-4007.
Wakita and Wands, “Specific Inhibition of Hepatitis C Virus Expression by Antisense Oliogdeoxynucleotides”,J. Biol. Chem.1994 269:14205-14210.
Rothenberg et al., “Oligonucleotides as anti-sense inhibitors of gene expression: therapeutic implications”,J. Natl. Cancer Inst. 1989 81:1539-1544.
Zon G. et al., “Oligonucleotide analogues as potential chemotherapeutic agents”,Pharmaceutical Res. 1987 5:539-549.
Anderson Kevin P.
Dorr F. Andrew
Hanecak Ronnie C.
Kwoh T. Jesse
Nozaki Chikateru
Guzo David
Isis Pharmaceuticals , Inc.
ISIS Pharmaceuticals Patent Dept.
LandOfFree
Compositions and methods for treatment of hepatitis C... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for treatment of hepatitis C..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for treatment of hepatitis C... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3678341